NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 909.9 DKK | +3.02% |
|
+6.87% | +30.34% |
| 05:08pm | Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank... |  |
| 04:31pm | Denmark faces Wegovy shortage due to rising demand, medicines agency says | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 29TCr 4.19TCr 3,49900Cr | Sales 2025 * | 35TCr 5.06TCr 4,22000Cr | Capitalization | 3,93500Cr 57TCr 47,56100Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 10TCr 1.51TCr 1,25800Cr | Net income 2025 * | 13TCr 1.83TCr 1,53000Cr | EV / Sales 2024 * | 13.6 x |
| Net Debt 2024 * | 1.33TCr 193.15Cr 16TCr | Net cash position 2025 * | 1.26TCr 182.92Cr 15TCr | EV / Sales 2025 * | 11.2 x |
| P/E ratio 2024 * |
38
x | P/E ratio 2025 * |
31.2
x | Employees | 66,015 |
| Yield 2024 * |
1.34% | Yield 2025 * |
1.61% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +3.02% | ||
| 1 week | +6.87% | ||
| Current month | +0.81% | ||
| 1 month | +3.49% | ||
| 3 months | +9.32% | ||
| 6 months | +31.20% | ||
| Current year | +30.34% |
1 week
857.10
909.90
1 month
826.70916.90
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.56% | ||
| 10.45% | 5 M€ | +12.51% | ||
| 5.40% | 17 M€ | +6.60% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 909.9 | +3.02% | 4 150 455 |
| 08/24/08 | 883.2 | +0.07% | 2,737,492 |
| 07/24/07 | 882.6 | +3.66% | 9,320,634 |
| 06/24/06 | 851.4 | +0.09% | 1,874,622 |
Delayed Quote Nasdaq Copenhagen, May 13, 2024 at 08:29 pm IST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.34% | 57TCr | |
| +29.07% | 68TCr | |
| -3.82% | 36TCr | |
| +17.75% | 33TCr | |
| +4.54% | 28TCr | |
| +16.06% | 24TCr | |
| +9.32% | 21TCr | |
| -6.83% | 20TCr | |
| +7.85% | 17TCr | |
| -0.69% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
